Home/Filings/4/0001209191-22-021151
4//SEC Filing

Hoelscher Paul W. 4

Accession 0001209191-22-021151

CIK 0001492426other

Filed

Mar 24, 8:00 PM ET

Accepted

Mar 25, 6:38 PM ET

Size

21.5 KB

Accession

0001209191-22-021151

Insider Transaction Report

Form 4
Period: 2022-03-23
Hoelscher Paul W.
EVP, Finance
Transactions
  • Exercise/Conversion

    Ordinary Shares

    2022-03-23$15.96/sh+26,090$416,39627,139 total
  • Sale

    Ordinary Shares

    2022-03-23$110.01/sh11,699$1,287,018160,527 total(indirect: By LLC)
  • Sale

    Ordinary Shares

    2022-03-25$110.00/sh663$72,930158,383 total(indirect: By LLC)
  • Gift

    Ordinary Shares

    2022-03-0766,6261,049 total
  • Gift

    Ordinary Shares

    2022-03-07+66,626245,015 total(indirect: By Trust)
  • Sale

    Ordinary Shares

    2022-03-23$110.00/sh26,090$2,870,0021,049 total
  • Sale

    Ordinary Shares

    2022-03-24$110.00/sh1,481$162,910159,046 total(indirect: By LLC)
  • Gift

    Ordinary Shares

    2022-03-07172,22672,789 total(indirect: By Trust)
  • Gift

    Ordinary Shares

    2022-03-07+172,226172,226 total(indirect: By LLC)
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2022-03-2326,09030,275 total
    Exercise: $15.96Exp: 2024-06-26Ordinary Shares (26,090 underlying)
Footnotes (5)
  • [F1]These securities are held of record by Riviera Equity LLC. The Reporting Person and his spouse share voting power over the securities held by Riviera Equity LLC.
  • [F2]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 15, 2021.
  • [F3]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.00 to $110.115 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F4]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on September 15, 2021.
  • [F5]The option is fully vested and exercisable.

Issuer

Horizon Therapeutics Public Ltd Co

CIK 0001492426

Entity typeother

Related Parties

1
  • filerCIK 0001611468

Filing Metadata

Form type
4
Filed
Mar 24, 8:00 PM ET
Accepted
Mar 25, 6:38 PM ET
Size
21.5 KB